Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Weight Management
Vasculature-targeting peptide that selectively destroys adipose blood vessels.
Peptide B
Weight Management
Dual GIP/GLP-1 receptor agonist delivering unprecedented weight loss and metabolic benefits.
Typical vial
5 mg
Typical dose
Per kg dosing (research-only) mcg
Half-life
~hours
FDA status
Not FDA approved.
Typical vial
5 mg
Typical dose
2500-15000 mcg
Half-life
~5 days (120 hours)
FDA status
FDA approved. Mounjaro (2022) for type 2 diabetes, Zepbound …
FTPP-Adipotide effects
Tirzepatide effects
FTPP-Adipotide side effects
Tirzepatide side effects
FTPP-Adipotide dosing ranges
Animal research (rhesus monkey model)
0.43 mg/kg · Daily SubQ × 28 days · Per published protocol
Human self-experimentation
Not recommended · — · —
Tirzepatide dosing ranges
Type 2 diabetes (Mounjaro)
2500-15000 mcg · Once weekly (SubQ) · Ongoing as prescribed
Weight management (Zepbound)
2500-15000 mcg · Once weekly (SubQ, titrated over 20 weeks) · Ongoing as prescribed
FTPP-Adipotide: Vasculature-targeting peptide that selectively destroys adipose blood vessels. Typical dose Per kg dosing (research-only) mcg. Tirzepatide: Dual GIP/GLP-1 receptor agonist delivering unprecedented weight loss and metabolic benefits. Typical dose 2500-15000 mcg. Both fall under the Weight Management category.
Stacking FTPP-Adipotide with Tirzepatide is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
FTPP-Adipotide is typically dosed: Daily SubQ × 28 days for Animal research (rhesus monkey model); — for Human self-experimentation. Tirzepatide is typically dosed: Once weekly (SubQ) for Type 2 diabetes (Mounjaro); Once weekly (SubQ, titrated over 20 weeks) for Weight management (Zepbound).
FTPP-Adipotide: Not FDA approved. Tirzepatide: FDA approved. Mounjaro (2022) for type 2 diabetes, Zepbound (2023) for chronic weight management, and (2024) for obstructive sleep apnea in adults with obesity.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free